Hyperion Therapeutics is a biopharmaceutical company focused on developing treatments for urea cycle disorders and other rare diseases that is headquartered in South San Francisco, California and was founded in 2006 by Mark Blumling.
On January 5, 2007 Hyperion Therapeutics completed their series A funding round with an undisclosed amount of funding from Sofinnova Ventures, New Enterprise Associates, and Highland Capital Partners.
On September 5, 2007 Hyperion Therapeutics completed their series B funding round with $40 million in funding from Sofinnova Ventures, New Enterprise Associates, Highland Capital Partners, and Washington Research Foundation.
On June 30, 2009 Hyperion Therapeutics completed their series C funding round with $60 million in funding from Bay City Capital (lead investor), Sofinnova Ventures, New Enterprise Associates, Highland Capital Partners, and Panorama Capital.
On April 18, 2011 Hyperion Therapeutics completed their venture funding round with $17.5 million in funding from undisclosed investors.
On March 30, 2015 Horizon Pharmaceuticals reached an agreement with Hyperion Therapeutics to purchase the company for $46 per share for approximately $1.1 billion total. The share purchase price of $46 per share was ~35% above Hyperion Therapeutics share price volume weighted average for the previous 60 days.
Medicis and Hyperion Therapeutics Announce Strategic Collaboration
Medicis Pharmaceutical Corporation
PRESS RELEASE: Hyperion Therapeutics Announces Senior Management Team and $15M Financing Event
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.